These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28739492)

  • 1. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
    Viscogliosi G; Chiriac IM; Ettorre E
    J Am Med Dir Assoc; 2017 Sep; 18(9):799-802. PubMed ID: 28739492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
    Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
    J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.
    Zhong KX; Tariot PN; Mintzer J; Minkwitz MC; Devine NA
    Curr Alzheimer Res; 2007 Feb; 4(1):81-93. PubMed ID: 17316169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Citalopram Compared With Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
    Viscogliosi G; Chiriac IM; Ettorre E
    J Am Med Dir Assoc; 2018 Jan; 19(1):89-90. PubMed ID: 29153751
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
    Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
    Ho T; Pollock BG; Mulsant BH; Schantz O; Devanand DP; Mintzer JE; Porsteinsson AP; Schneider LS; Weintraub D; Yesavage J; Drye LT; Munro CA; Shade DM; Lyketsos C; Bies R
    Br J Clin Pharmacol; 2016 Sep; 82(3):784-92. PubMed ID: 27145364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
    Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
    Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
    Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
    Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
    Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?
    Angelini A; Bendini C; Neviani F; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():35-43. PubMed ID: 17317431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.